BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 12884908)

  • 1. c-Met: structure, functions and potential for therapeutic inhibition.
    Ma PC; Maulik G; Christensen J; Salgia R
    Cancer Metastasis Rev; 2003 Dec; 22(4):309-25. PubMed ID: 12884908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
    Maulik G; Shrikhande A; Kijima T; Ma PC; Morrison PT; Salgia R
    Cytokine Growth Factor Rev; 2002 Feb; 13(1):41-59. PubMed ID: 11750879
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.
    Dietrich S; Uppalapati R; Seiwert TY; Ma PC
    J Environ Pathol Toxicol Oncol; 2005; 24(3):149-62. PubMed ID: 16050800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
    Sattler M; Salgia R
    Curr Oncol Rep; 2007 Mar; 9(2):102-8. PubMed ID: 17288874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
    Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
    Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
    Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
    Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A simple view on lung cancer biology: the MET pathway].
    Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
    Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
    Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R
    Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
    Christensen JG; Burrows J; Salgia R
    Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
    Comoglio PM
    EXS; 1993; 65():131-65. PubMed ID: 8380735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
    Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
    Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis.
    Mitra AK; Sawada K; Tiwari P; Mui K; Gwin K; Lengyel E
    Oncogene; 2011 Mar; 30(13):1566-76. PubMed ID: 21119598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review).
    To CT; Tsao MS
    Oncol Rep; 1998; 5(5):1013-24. PubMed ID: 9683803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MET: a critical player in tumorigenesis and therapeutic target.
    Graveel CR; Tolbert D; Vande Woude GF
    Cold Spring Harb Perspect Biol; 2013 Jul; 5(7):. PubMed ID: 23818496
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
    Matsumoto K; Nakamura T; Sakai K; Nakamura T
    Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
    You WK; McDonald DM
    BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.
    Weidner KM; Sachs M; Birchmeier W
    J Cell Biol; 1993 Apr; 121(1):145-54. PubMed ID: 8384622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
    Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
    J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
    Accornero P; Pavone LM; Baratta M
    Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.